The Canadian government has allowed people suffering from depression to take psilocybin, the active ingredient in hallucinogenic mushrooms, KNIFE magazine reported, citing Vice.
Back in the summer, authorities granted access to psilocybin to four end-stage cancer patients. From now on, it can be used for other, non-fatal diseases, for example, depression.
The first patient who was allowed to treat depression with this substance was 67-year-old Mona Strelaeff from Victoria, Canada. 12 years ago, she was diagnosed with breast cancer, which caused the woman to develop a mental disorder. In addition to depression due to oncology, experiences caused by childhood trauma were added.
On November 5, the patient took psilocybin under the supervision of a family doctor and clinical psychologist. The therapy helped her cope with difficult memories, she said. Now, according to her, they "are not afraid of a damn thing."
Previously, the production, storage and sale of psilocybin in Canada was prohibited, with the exception of laboratory tests.
The use of the substance to treat depression was approved in the United States back in 2018. In November of this year, the use of hallucinogenic mushrooms for therapeutic purposes was first allowed in the state of Oregon.
Previously, scientists from the Johns Hopkins School of Medicine found that psilocybin is four times more effective than antidepressants for depressive disorder.